in Re	Application of: REIMA	ANN et al.			Ar	t Unit: 1632				
Application No.: 09/241,595						Ex	aminer: A Beckerleg			"They
Filed: February 2, 1999						Wa	ashington, D.C.		<u>ن</u>	
For: DELIVERY OF IMMUNOGENIC MOLECULES VIA HBSAG PARTICLES							y 's Docket: REIMAN	IN=1	_	
							-			٠, ٠, ٠, ٠, ٠, ٠, ٠, ٠, ٠, ٠, ٠, ٠, ٠, ٠
TUE	COMMISSIONED OF	DATENTO				Ua	te: May 3, 2001	,	4	
THE COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231								0	asi	
Sir:								Po	enti	
								١ ($9\gamma uv$	-12K
	itted herewith is a [] bove-identified application		t [X] SUPPLEMEN	TAL RESPONS	E	-				5/11
	Small entity status of the		on under 37 CFR 1	.9 and 1.27 has	been es	tablished by a ver	rified statement previ	ously su	hmitted	BAIC
[]	A verified statement to	establish si	mall entity status ur	nder 37 CFR 1.9	and 1.2	7 is enclosed.	mod disternent previ	ously su	omitted	1000
	No additional fee is red	•								
[]	The fee has been calc	ulated as sh	own below:							
	(Col.) (Col. 2) (Col. 3)						SMALL ENTITY			N SMALL ENTIT
	CLAIMS		HIGHEST	PRESENT]	RATE	ADDITIONAL	OR	RATE	ADDITIONA
	REMAINING AFTER		NO. PREVIOUSLY	EXTRA			FEE	"	10010	FEE
	AMENDMENT		PAID	EQUALS				ļ		
TOTAL	* 30	MINUS	** 30	0		x 9	\$	1	x 18	\$
INDEP.	* 4	MINUS	*** 4	0]	x 40	\$] .	x 80	\$
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM + 135							\$		+ 270	\$
				A	DDITIO	NAL FEE TOTAL	\$	OR	TOTAL	\$
* 1	itha ambaile Oal 4 is 1	41 11								
	f the entry in Col. 1 is I f the "Highest Number				an 20 w	rite "20" in this en	200			
	the "Highest Number									
7	he "Highest Number F	Previously P	aid For" (total or inc	lanandant) is the	a biabaat	mumbau faund fa	db			
'n	umber of claims origin	ally filed.	aid for (total of life	rependent) is the	e nignesi	number lound tr	om the equivalent bo	x in Col.	1 of a prior amer	idment of the
[XX] C	Conditional Petition for	Extension o	f Time							
11	any extension of time	for a respon	nse is required, app	licant requests t	that this I	be considered a p	etition therefor.			
[] It	is hereby netitioned for	or an extens	ion of time in accor	dance with 27 C	·CD 4 40	C(a) The				
, p	is hereby petitioned for elow:	or an extens	ion or time in accor	uance with 37 C	FR 1.13	o(a). The approp	nate fee required by	37 CFR	1.17 is calculated	as shown
	Small Entity				Othe	Other Than Small Entity				
	Response Filed Within				Resp	Response Filed Within				
	[] First	- \$ 9	55.00		[]	First -	\$ 110.00			
	[] Second	- \$ 19	95.00		[]	Second -	\$ 390.00			•
	[] Third	- \$ 44	15.00		[]	Third -	\$ 890.00			
	[] Fourth	- \$ 69	95.00		[]	Fourth -	\$ 1390.00			
	Month After Time Period Set Mo					th After Time Period Set				
	[] Less fees (\$) alı	ready paid for r	month(s) extensi	ion of tim	ne on	·			
[] P	lease charge my Depo	sit Account	No. 02-4035 in the	amount of \$						
	redit Card Payment Fo									

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does <u>not</u> include patent issue fees under 37 CFR §1.18.

__ is attached (check no.).

BROWDY AND NEIMARK

Attorneys for Applicant(s)

Registration No. 37,971

Facsimile: Telephone: (202) 737-3528 (202) 628-5197

[] A check in the amount of \$_

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: REIMANN=1

In re Application of:

Jorg REIMANN et al

Art Unit: 1632

Appln. No.: 09/241,595

Confirmation No.: 8928

Filed: February 2, 1999

For: DELIVERY OF IMMUNOGENIC MOLECULES VIA HbsAg PARTICLES

ATTY.'S DOCKET: REIMANN=1

Examiner: A. Beckerleg

Nath Unit: 1632

Mashington, D.C.

May 3, 2001

May 3, 2001

SUPPLEMENTAL RESPONSE

Honorable Commissioner for Patents Washington, D.C. 20231

Sir:

Supplemental to the response filed March 20, 2001, on which applicants continue to primarily rely, attached hereto are copies of the articles cited in the response filed March 20, 2001. The attached Schirmbeck et al., International Immunology 11(7):1093-1102 (1999), and Böhm et al., Vaccine 16:949-954 (1998), articles were misidentified as Reimann et al. (even though J. Reimann is a co-author) on pages 4 and 7 of the response filed March 20, 2001.

The Ogg et al., <u>Science</u> 279:2103-2106 (1998), article attached hereto was inadvertently not cited on page 10 with the other HIV-related publications in the response filed March 20, 2001.

İn re' of Appln. N 09/241,595

Favorable consideration and allowance are earnestly urged.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C. Attorneys for Applicant(s)

By

FINE MEDICAL

Allen C. Yun

Registration No. 37,971

ACY:pr

Telephone No.: (202) 628-5197 Facsimile No.: (202) 737-3528

F:\,C\cohn\Reimann1\Pto\supplemental response.wpd